BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

Exclusion Criteria

• •Significant pleural effusion
• •CNS metastases by head CT scan or MRI within the past 4 weeks
• •Pregnant or breast-feeding
• •Prior chemotherapy or monoclonal antibodies for other cancers within 5 years prior to registration
• •Prior chemotherapy for lung cancer
• •Prior chest radiotherapy
• •Ongoing (lasting \> 14 days) or active infection or ongoing (lasting \> 14 days) fever within the past 6 months
• •Gross hemoptysis ≥ grade 2 (defined as ≥ ½ teaspoon of bright red blood per episode) within the past 3 months
• •Bleeding ≥ grade 2 or any bleeding requiring intervention
• •Clinically significant cardiovascular disease
• •Myocardial infarction within the past 6 months
• •New York Heart Association class III-IV congestive heart failure
• •Unstable angina pectoris
• •Serious cardiac arrhythmia requiring medication within the past 4 weeks
• •History of hypertensive crisis or hypertensive encephalopathy
• •Stroke or transient ischemic attack within the past 6 months
• •Peripheral vascular disease ≥ grade 2 within the past 6 months
• •Abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months
• •Psychiatric illness or social situation that would limit compliance with study requirements
• •History of uncontrolled hypertension (i.e., blood pressure ≥ 150/100 mm Hg) while on stable regimen of antihypertensive therapy
• •Significant traumatic injury or serious non-healing wound, ulcer, or bone fracture within the past 4 weeks
• •Concurrent major surgical procedure
• •Having anticipated major surgical procedure(s) during the course of the study
• •Concurrent daily aspirin (\> 325 mg/day) or nonsteroidal anti-inflammatory agents (NSAIDs) known to inhibit platelet function
• •Recognized immunodeficiency disease, including cellular immunodeficiencies, hypogammaglobulinemia or dysgammaglobulinemia, or hereditary or congenital immunodeficiencies
• •Pre-existing medical condition requiring chronic steroids or immunosuppressive therapy
• •Autoimmune disease
• •Known hepatitis B or C
• •Immunotherapy (e.g., interferon, interleukin, sargramostim \[GM-CSF\], or filgrastim \[G-CSF\]) within 28 days prior to registration
• •Prior splenectomy
• •Hypersensitivity to any component of bevacizumab
• •Prior core biopsy or any other minor surgical procedure, excluding the placement of a vascular access device, within 7 days prior to registration
• •Progressive disease or unevaluable disease per RECIST criteria upon post- consolidation chemotherapy evaluation
• •Autoimmune disease